Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 8/20 | 0.70 |
| ▸ | P4HTM | Q9NXG6 | 8/20 | 0.69 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13408266 | 0.93 | VHL (0.69) | VHLP4HTMEGLN1 | |
| SCHEMBL13408252 | 0.92 | VHL (0.68) | VHLP4HTM | |
| SCHEMBL13408239 | 0.92 | VHL (0.68) | VHLP4HTMF3EGLN1 | |
| SCHEMBL13408225 | 0.89 | VHL (0.73) | VHLP4HTMEGLN1 | |
| SCHEMBL8197353 | 0.89 | VHL (0.72) | VHLP4HTMEGLN1 | |
| SCHEMBL8182386 | 0.88 | P4HTM (0.72) | VHLP4HTMEGLN1 | |
| SCHEMBL13408262 | 0.88 | P4HTM (0.83) | VHLP4HTMF3EGLN1 | |
| SCHEMBL8200168 | 0.88 | P4HTM (0.72) | VHLP4HTMF3EGLN1 | |
| SCHEMBL8197529 | 0.86 | P4HTM (0.72) | VHLP4HTMEGLN1 | |
| SCHEMBL8183323 | 0.86 | VHL (0.77) | VHLP4HTMEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | DCK, THPO, QDPR | VHL 25/4885P4HTM 412/4885F3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.